ТОЦИЛИЗУМАБ В ЛЕЧЕНИИ ДЕТЕЙ С СИСТЕМНЫМ ВАРИАНТОМ ЮВЕНИЛЬНОГО АРТРИТА: АНАЛИЗ ФАКТОРОВ, ВЛИЯЮЩИХ НА ЭФФЕКТИВНОСТЬ ТЕРАПИИ В ДОЛГОСРОЧНОМ ПЕРИОДЕ
https://doi.org/10.15690/vsp.v14i2.1292
Аннотация
Об авторах
М. И. Каледа
Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Российская Федерация
Россия
Россия
врач-ревматолог детского ревматологического отделения НИИ ревматологии им. В.А. Насоновой Адрес: 115522, Москва, Каширское шоссе, д. 34А, тел.: +7 (499) 614-44-64
И. П. Никишина
Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Российская Федерация
Россия
Россия
Список литературы
1. Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of Pediatric Rheumatology. 6th edn. Philadelphia: Saunders Company. 2001. P. 218–322.
2. Alexeeva E.I., Litvitskii P.F. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Pod obshch. red. A.A. Baranova [Juvenile Rheumatoid Arthritis: Etiology, Pathogenesis, Clinical Algorithms for Diagnosis and Treatment. Guideline for Doctors, Teachers, Scientists. Edited by A.A. Baranov]. Moscow, VEDI, 2007. 368 p.
3. De Benedetti F., Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J. Rheumatology. 1998; 25 (2): 203–207.
4. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., Iwata N., Umebayashi H., Murata T., Miyoshi M., Tomiita M., Nishi mo-to N., Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371:998-1006. Doi: 10.1016/S0140-6736(08)60454-7.
5. Woo P., Wilkinson N., Prieur A. M., Southwood T., Leone V., Livermore P., Wythe H., Thomson D., Kishimoto T. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. 2005;7: 1281–1288. Doi: 10.1186/ar1826.
6. De Benedetti F., Brunner H. I., Allen R., Brown D., Chaitow J., Pardeo M., Espada G., Flato B., Horneff G., Devlin C. et al. Tocilizumab Is efficacious in patients with systemic juvenile idiopathic arthritis across baseline demographic and disease characteristics and prior/baseline treatments: 52-week data from a phase 3 clinical trial. Arthritis Rheum. 2011;63 (Suppl.): 1029–1030.
7. Petty R. E., Southwood T. R., Manners P., Baum J., Glass D. N., Goldenberg J. et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004; 31 (2): 390–392.
8. Steinbrocker O., Traeger C. H., Batterman R. C. Therapeutic criteria in rheumatoid arthritis. Arthr. Rheum. 1988; 31: 315–324.
9. Giannini E. H., Ruperto N., Ravelli A., Lovell D. J., Felson D. T., Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997; 40: 1202–1209.
10. Wallace C. A., Giannini E. H., Huang B., Itert L., Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken). 2011; 63: 929. Doi: 10.1002/acr.20497.
11. Reiff A. Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab — the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment. Biol. Ther. 2012; 2: 1. Doi: 10.1007/ s13554-012-0001-6.
12. De Benedetti F., Brunner H. I., Ruperto N., Kenwright A., Wright S., Calvo I., Cuttica R., Ravelli A., Schneider R., Woo P., Wouters C., Xavier R., Zemel L., Baildam E., Burgos-Vargas R., Dolezalova P., Garay S. M., Merino R., Joos R., Grom A., Wulffraat N., Zuber Z., Zulian F., Lovell D., Martini A. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012; 367: 2385–2395. Doi: 10.1056/NEJMoa1112802.
13. Baranov A.A., Alexeeva E.I., Valieva S.I., Bzarova T.M., Mitenko E.V., Denisova R.V., Fetisova A.N., Sleptsova T.V., Isaeva K.B., Chistyakova E.G. Retrospective analysis of efficacy and safety of tocilizumab in patients with severe systemic juvenile idiopathic arthritis: 12 months of follow-up. Voprosy sovremennoi pediatrii = Current pediatrics. 2013;12(2):26–34. DOI: http://dx.doi.org/10.15690/vsp.v12i2.617
14. Alexeeva E.I., Baranov A. A., Valieva S. I., Denisova R. V., Bzarova T. M., Isaeva K. B., Sleptsova T. V., Mitenko E. V., Taybulatov N. I., Chistyakova E. G., Fetisova A. N. Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months. ISRN Immunology. 2013; Article ID 548312: 8 p. http://dx.doi.org/10.1155/2013/548312
15. Malattia C., Ruperto N., Palmisani E., Pederzoli S., Pistorio A., Brunner H., Cuttica R. J., Calvo I., Garay S. M., Eleftheriou D., Wouters C., Wang J., Devlin C., Lovell D. J., Martini A., De Benedetti F., Ravelli A. Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. Arthritis Rheum. 2014; 66 (Suppl. 11): 96–97. Doi: 10.1002/art.38482.
16. Aoki C., Inaba Y., Choe H., Kaneko U., Hara R., Miyamae T., Imagawa T., Mori M., Oba M. S., Yokota S., Saito T. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J. Rheumatol. 2014; 41: 1171–1177. Doi: 10.3899/jrheum.130924.
17. De Benedetti F., Ruperto N., Baildam E., Burgos-Vargas R., Horneff G., Huppertz H. I., Minden K., Myones B. L., Onel K., Wang J., Bharucha K. N., Lovell D. J., Martini A., Brunner H. A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. Arthritis Rheum. 2014; 66:23–S24. Doi: 10.1002/art.38422.
18. De Benedetti F., Ruperto N., Brunner H., Grom A. A., Wulffraat N., Henrickson M., Jerath R., Kimura Y., Kadva A. K., Wang J., Martini A., Lovell D. J. A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. Arthritis Rheumatol. 2014; 66: 8–9. Doi: 10.1002/art.38417.
19. Kessler E., Vora S., Verbsky J. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr. Rheum. Online J. 2012; 10 (1): 30. Doi: 10.1186/1546-0096-10-30.
20. Ravelli A., Schneider R., Weitzman S., Devlin C., Daimaru K., Yokota S., Takei S., De Benedetti F. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Arthritis Rheum. 2014; 66 (Suppl. 11): 83–84. Doi: 10.1002/art.38472.
21. Mitenko E.V., Alexeeva E.I., Denisova R.V., Sleptsova T.V. Clinical case of tocilizumab therapy in a patient with systemic juvenile idiopathic arthritis. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013;10(4):154–158. DOI: http://dx.doi.org/10.15690/pf.v10i4.771
22. Russo R., Katsicas M. Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy. Pediatric Rheumatology. 2011, vol. 9, supplement 1, article 186.
23. Baranov A.A., Alexeeva E.I., Valieva S.I., Bzarova T.M., Mitenko E.V., Denisova R.V., Fetisova A.N., Sleptsova T.V., Isaeva K.B., Chistyakova E.G., Taibulatov N.I., Chomakhidze A.M. Treatment with genetically engineered biological agents: efficacy and safety of changeover. Voprosy sovremennoi pediatrii = Current pediatrics. 2014;13(1):33–51. DOI: http://dx.doi.org/10.15690/vsp.v13i1.910
Рецензия
Для цитирования:
Каледа М.И., Никишина И.П. ТОЦИЛИЗУМАБ В ЛЕЧЕНИИ ДЕТЕЙ С СИСТЕМНЫМ ВАРИАНТОМ ЮВЕНИЛЬНОГО АРТРИТА: АНАЛИЗ ФАКТОРОВ, ВЛИЯЮЩИХ НА ЭФФЕКТИВНОСТЬ ТЕРАПИИ В ДОЛГОСРОЧНОМ ПЕРИОДЕ. Вопросы современной педиатрии. 2015;14(2):236-245. https://doi.org/10.15690/vsp.v14i2.1292
For citation:
Kaleda M.I., Nikishina I.P. TOCILIZUMAB IN THE TREATMENT OF CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS: ANALYSIS OF FACTORS INFLUENCING THE THERAPY EFFICIENCY IN THE LONG TERM. Current Pediatrics. 2015;14(2):236-245. (In Russ.) https://doi.org/10.15690/vsp.v14i2.1292
Просмотров: 903
Послать статью по эл. почте 
